In this study, researchers are testing a new medicine called SNP-ACTH (1-39) Gel for patients with a kidney condition known as primary membranous nephropathy (PMN). PMN is a disease where the kidneys have trouble filtering blood properly. The study is in two parts. In the first part, called Phase 3a, 16 patients will be given different doses of the gel to find the best amount to use. In the second part, Phase 3b, 132 patients will either receive the chosen dose of the gel or another medicine called rituximab to see which works better over 24 months.

• The study lasts for 24 months, with several check-ups along the way.
• Participation includes regular injections and health assessments.
• Patients should not have certain health conditions like diabetes or recent surgeries.

To join, patients must have specific kidney test results and cannot have certain other health issues. This research aims to improve treatment for people with PMN, potentially offering a new option for managing their condition. If you are interested, discuss with your doctor to see if you qualify.